OBJECTIVE: Isolated diastolic dysfunction is present in 40% of heart failure patients. It has been attributed to myocardial fibrosis and related to cardiovascular risk factor exposure. We hypothesized that simvastatin will improve these dynamics in experimental hypercholesterolemia (HC). METHODS: Three groups of pigs were studied after 12 weeks of normal (N) diet, HC diet, or HC diet with simvastatin (80 mg/day) treatment. Cardiac function was assessed by electron beam computed tomography (EBCT) and percentage of myocardium occupied by microvessels (myocardial vascular fraction) was calculated by micro-CT. Collagen content was determined by Sirius red staining and confirmed by a quantitative, hydroxyoproline-based assay. RESULTS: Compared with N, LDL serum concentration was higher in HC and HC+simvastatin (1.0±0.1 vs. 7.9±1.7 and 9.6±1.2 mmol/L, p<0.05 for both). Cardiac early diastolic filling was reduced in HC compared with N (102.4±11.3 vs. 151.1±12.1 mL/s; p<0.05) but restored in HC+simvastatin (176.8±21.3 mL/s, p<0.05 vs. HC). Compared with N, myocardial vascular fraction was higher in HC but not in HC+simvastatin (1.98±0.84 vs. 4.48±0.31 and 2.95±0.95%; p<0.05 for HC vs. N). Myocardial collagen content was higher in HC than in HC+simvastatin and N (4.72±1.03 vs. 1.62±0.12 and 1.21±0.24% area staining; p<0.05 for HC vs. N), which was attributable mainly to an increase in collagen III (2.90±0.48 vs. 1.62±0.12 and 1.21±0.24% area staining; p<0.05 for HC vs. N). CONCLUSIONS: Simvastatin is able to prevent diastolic dysfunction in experimental HC independent of its lipid lowering effect. This beneficial effect is, at least partially, due to a decrease in myocardial fibrosis and angiogenesis.
OBJECTIVE: Isolated diastolic dysfunction is present in 40% of heart failurepatients. It has been attributed to myocardial fibrosis and related to cardiovascular risk factor exposure. We hypothesized that simvastatin will improve these dynamics in experimental hypercholesterolemia (HC). METHODS: Three groups of pigs were studied after 12 weeks of normal (N) diet, HC diet, or HC diet with simvastatin (80 mg/day) treatment. Cardiac function was assessed by electron beam computed tomography (EBCT) and percentage of myocardium occupied by microvessels (myocardial vascular fraction) was calculated by micro-CT. Collagen content was determined by Sirius red staining and confirmed by a quantitative, hydroxyoproline-based assay. RESULTS: Compared with N, LDL serum concentration was higher in HC and HC+simvastatin (1.0±0.1 vs. 7.9±1.7 and 9.6±1.2 mmol/L, p<0.05 for both). Cardiac early diastolic filling was reduced in HC compared with N (102.4±11.3 vs. 151.1±12.1 mL/s; p<0.05) but restored in HC+simvastatin (176.8±21.3 mL/s, p<0.05 vs. HC). Compared with N, myocardial vascular fraction was higher in HC but not in HC+simvastatin (1.98±0.84 vs. 4.48±0.31 and 2.95±0.95%; p<0.05 for HC vs. N). Myocardial collagen content was higher in HC than in HC+simvastatin and N (4.72±1.03 vs. 1.62±0.12 and 1.21±0.24% area staining; p<0.05 for HC vs. N), which was attributable mainly to an increase in collagen III (2.90±0.48 vs. 1.62±0.12 and 1.21±0.24% area staining; p<0.05 for HC vs. N). CONCLUSIONS:Simvastatin is able to prevent diastolic dysfunction in experimental HC independent of its lipid lowering effect. This beneficial effect is, at least partially, due to a decrease in myocardial fibrosis and angiogenesis.
Authors: Martin Rodriguez-Porcel; Xiang-Yang Zhu; Alejandro R Chade; Beatriz Amores-Arriaga; Noel M Caplice; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: Am J Physiol Heart Circ Physiol Date: 2005-10-07 Impact factor: 4.733
Authors: Gregory L Brower; Jason D Gardner; Mary F Forman; David B Murray; Tetyana Voloshenyuk; Scott P Levick; Joseph S Janicki Journal: Eur J Cardiothorac Surg Date: 2006-08-28 Impact factor: 4.191
Authors: Elena Daghini; Andrew N Primak; Alejandro R Chade; Xiangyang Zhu; Erik L Ritman; Cynthia H McCollough; Lilach O Lerman Journal: Invest Radiol Date: 2007-05 Impact factor: 6.016
Authors: Xiang-Yang Zhu; Elena Daghini; Martin Rodriguez-Porcel; Alejandro R Chade; Claudio Napoli; Amir Lerman; Lilach O Lerman Journal: Atherosclerosis Date: 2006-09-22 Impact factor: 5.162
Authors: James J M Greer; Aman K Kakkar; John W Elrod; Lewis J Watson; Steven P Jones; David J Lefer Journal: Am J Physiol Heart Circ Physiol Date: 2006-07-14 Impact factor: 4.733
Authors: JoAnne Micale Foody; Rahman Shah; Deron Galusha; Frederick A Masoudi; Edward P Havranek; Harlan M Krumholz Journal: Circulation Date: 2006-02-20 Impact factor: 29.690
Authors: Ahmad A Elesber; Margaret M Redfield; Charanjit S Rihal; Abhiram Prasad; Shahar Lavi; Ryan Lennon; Verghese Mathew; Lilach O Lerman; Amir Lerman Journal: Am Heart J Date: 2007-06 Impact factor: 4.749
Authors: Xiang-Yang Zhu; Elena Daghini; Alejandro R Chade; Claudio Napoli; Erik L Ritman; Amir Lerman; Lilach O Lerman Journal: J Am Soc Nephrol Date: 2007-03-07 Impact factor: 10.121
Authors: Joerg Herrmann; Christine Wohlert; Ardan M Saguner; Ana Flores; Lisa L Nesbitt; Alejandro Chade; Lilach O Lerman; Amir Lerman Journal: Eur J Heart Fail Date: 2013-04-24 Impact factor: 15.534
Authors: Oana Sorop; Jens van de Wouw; Selena Chandler; Vahagn Ohanyan; Johnathan D Tune; William M Chilian; Daphne Merkus; Shawn B Bender; Dirk J Duncker Journal: Cardiovasc Res Date: 2020-03-01 Impact factor: 10.787